Neftel K A, Wälti M, Schulthess H K, Gubler J
Klin Wochenschr. 1984 Jan 2;62(1):25-9. doi: 10.1007/BF01725189.
We have recently shown that high-dose intravenous therapy with penicillin-G always results in both sensitised lymphocytes and rise of anti-penicilloyl IgG antibodies. If penicillin-G is strictly given as freshly prepared bolus doses this sensitisation is prevented. In 193 patients, intravenous treatment with penicillin-G without special precautions (bolus doses stored up to 36 h at 4 degrees C or continuous infusions) led to 8.3% definite, 6.7% probable and 14.0% possible adverse reactions. In 116 patients treated exclusively with freshly dissolved doses, 0.9% definite, 1.7% probable and 4.3% possible reactions occurred. Whereas haemolytic anaemia (7) and neutropenia (12) were observed in 19 cases of the first group no such reactions were seen in the second group. Strict application of freshly prepared single doses prevents the majority of adverse reactions following highdose intravenous penicillin-G therapy. Degradation and transformation products formed in vitro are therefore the causative agents rather than the penicillin molecule itself.
我们最近发现,大剂量静脉注射青霉素G总会导致致敏淋巴细胞以及抗青霉噻唑IgG抗体升高。如果严格将青霉素G以新配制的大剂量推注给药,这种致敏反应是可以预防的。在193例患者中,未采取特殊预防措施(大剂量推注在4℃储存长达36小时或持续输注)静脉注射青霉素G导致8.3%的明确不良反应、6.7%的可能不良反应和14.0%的潜在不良反应。在116例仅接受新溶解剂量治疗的患者中,发生了0.9%的明确反应、1.7%的可能反应和4.3%的潜在反应。第一组19例中观察到溶血性贫血(7例)和中性粒细胞减少(12例),而第二组未出现此类反应。严格应用新配制的单剂量可预防大剂量静脉注射青霉素G治疗后的大多数不良反应。因此,体外形成的降解产物和转化产物而非青霉素分子本身是致病因素。